Keating Financial Advisory Services’s Amphastar Pharmaceuticals AMPH Stock Holding History

Keating Financial Advisory Services’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$565	Buy	+28	New	+$565	﹤0.01%	2320

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Keating Financial Advisory Services's AMPH Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2026: 28 shares worth $565. The stake represents ﹤0.01% of the portfolio and ranks #2320 among its holdings.

210 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

Keating Financial Advisory Services held 28 shares of Amphastar Pharmaceuticals worth $565 as of Q2 2026.
Amphastar Pharmaceuticals was a new Keating Financial Advisory Services position in Q2 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2320 holding.
210 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.